European Archives - Page 280 of 1118 - European Medical Journal

Pride 2024: How can pharma leaders make a difference?

Hear from four pharma leaders on the benefits to employees and patients of workplaces that promote inclusivity for the LGBTQ+ community.

Pride Special: J&J's Edmond Chan on the value in being your authentic self

J&J’s Edmond Chan discusses how both the pharmaceutical and healthcare industries can do their best to support people from the LGBTQ+ community

Study Confirms Safety of Paternal Valproate Use Pre-Conception

Findings from a comprehensive nationwide cohort study from Denmark have demonstrated the safety of paternal valproate use during spermatogenesis.

Progestogens and Oral Contraceptives Equally Effective in Endometriosis Pain Management

New findings show that postoperative prescription of a long-acting progestogen, or the combined oral contraceptive pill, can reduce the recurrence of endometriosis-related pain.

Precision Genomic Testing Improves Survival in Paediatric Oncology

New research shows that integrating precision genomic testing with targeted therapies improves treatment responses and progression-free survival in pediatric oncology.

Algorithm-Based Referrals Enhance Palliative Care Access

An algorithm-based default referrals system has led to a fourfold increase in the use of specialty palliative care within a large community oncology network.

Prostate Cancer Treatment Linked to Increased Cardiovascular Risk

Significant cardiovascular risks associated with adding androgen receptor signalling inhibitors to standard androgen deprivation therapy in patients with advanced prostate cancer.

Ipsen Symposium at ESPGHAN 2024: PFIC Through a Different Lens: How Can You Change the Course of the Disease?

This video presents the satellite symposium hosted by Ipsen at the 56th Annual Meeting of the European Society for Paediatric…

Improved Prostate Cancer Diagnosis with AI

New research has shown that an AI system can more efficiently detect clinically significant prostate cancer on MRI compared to radiologists.

Acalabrutinib and Chemotherapy Enhance Survival in Mantle Cell Lymphoma

Frontline treatment with acalabrutinib, bendamustine, and rituximab shows promising results in reducing disease progression and death in older mantle cell lymphoma patients.